OCUL - オキュラ―・セラピュ―ティクス (Ocular Therapeutix Inc.)

OCULのニュース

   Ocular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development  2021/01/07 13:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the promotion of Michael Goldstein, MD, MBA, to the newly created position of President, Ophthalmology. Dr. Goldstein will continue to report to Antony Mattessich, Ocular’s President and Chief Executive Officer. With this promotion, Dr. Goldstein will be
   Ocular TherapeutixTM Announces Exercise of Underwriters’ Option to Purchase Additional Shares  2020/12/28 13:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the underwriters of its public offering that closed on December 18, 2020, have exercised in full their option to purchase an additional 558,750 shares of its common stock at the public offering price of $21.50 per share, less underwriting discounts
   Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock  2020/12/16 02:47:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 3,725,000 shares of its common stock at a public offering price of $21.50 per share for gross proceeds of approximately $80.1 million, before deducting underwriting discounts and commissions and other of
   Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock  2020/12/14 21:13:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has commenced an underwritten public offering of $75.0 million of its common stock. In addition, the Company is expected to grant the underwriters of the offering a 30-day option to purchase up to an additional $11.25 million of its common stock
   The Daily Biotech Pulse: Lilly Secures Additional Orders For COVID-19 Antibody Treatment, Decision Day For BioCryst, Kinnate Biopharma To Make Wall Street Debut  2020/12/03 12:46:12 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 2) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cerevel Therapeutics Holdings Inc (NASDAQ: CERE ) Fate Therapeutics Inc (NASDAQ: FATE ) Generation Bio Co (NASDAQ: GBIO ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Inhibrx Inc (NASDAQ: INBX ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Inspire Medical Systems Inc (NYSE: INSP ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Larimar Therapeutics Inc (NASDAQ: LRMR ) Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) (reacted to positive outlook for the cancer drug it sold to Ispen, which opens the possibility of realizing potential milestone payments) Myovant Sciences Ltd (NYSE: MYOV ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Olema Pharmaceuticals Inc (NASDAQ: OLMA ) Oncorus Inc (NASDAQ: ONCR ) OncoSec Medical Inc (NASDAQ: ONCS ) Pfizer Inc. (NYSE: PFE ) ( announced U.K. regulatory nod for emergency use of its coronavirus vaccine candidate) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Pulse Biosciences Inc (NASDAQ: PLSE ) Spero Therapeutics Inc (NASDAQ: SPRO ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Dec. 2) Histogen Inc (NASDAQ: HSTO ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) (shares will trade …
   The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback  2020/11/25 12:35:38 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24) AbbVie Inc (NYSE: ABBV ) Affimed NV (NASDAQ: AFMD ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cellectis SA (NASDAQ: CLLS ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Generation Bio Co (NASDAQ: GBIO ) Inspire Medical Systems Inc (NYSE: INSP ) Kronos Bio Inc (NASDAQ: KRON ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) NeoGenomics, Inc. (NASDAQ: NEO ) NGM Biopharmaceuticals Inc (NASDAQ: NGM ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Pulmonx Corp (NASDAQ: LUNG ) Relay Therapeutics Inc (NASDAQ: RLAY ) Sotera Health Co (NASDAQ: SHC ) (began trading on Nasdaq Friday following its IPO) Trinity Biotech plc (NASDAQ: TRIB ) Veracyte Inc (NASDAQ: VCYT ) Zai Lab Ltd – ADR (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 24) Advaxis, Inc. (NASDAQ: ADXS ) ( announced a public offering of common stock and warrants) Immunome Inc (NASDAQ: IMNM ) InMed Pharmaceuticals Inc (NASDAQ: INM ) Kiromic Biopharma Inc (NASDAQ: KRBP ) Maravai Lifesciences Holdings Inc (NASDAQ: MRVI ) debuted on Wall Street Friday) Qualigen …
   Ocular Therapeutix™ to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference  2020/11/23 13:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from December 1 to December 3, 2020. In addition to a fireside chat, the management team will host virtual investor meetings on Wednesday, December 2nd at the co
   Ocular Therapeutix, Inc. (NASDAQ:OCUL) Expected to Announce Earnings of -$0.10 Per Share  2020/11/18 15:12:56 Transcript Daily
Analysts forecast that Ocular Therapeutix, Inc. (NASDAQ:OCUL) will announce ($0.10) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Ocular Therapeutix’s earnings, with the lowest EPS estimate coming in at ($0.18) and the highest estimate coming in at $0.00. Ocular Therapeutix posted earnings per share of […]
   Analysts Expect Ocular Therapeutix, Inc. (NASDAQ:OCUL) Will Post Earnings of -$0.10 Per Share  2020/11/18 15:12:55 Transcript Daily
Brokerages forecast that Ocular Therapeutix, Inc. (NASDAQ:OCUL) will report earnings per share of ($0.10) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Ocular Therapeutix’s earnings, with estimates ranging from ($0.18) to $0.00. Ocular Therapeutix posted earnings of ($0.47) per share in the same quarter last year, which would suggest a […]
   The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration  2020/11/17 13:31:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16) Aligos Therapeutics Inc (NASDAQ: ALGS ) (announced multiple presentations at the Liver Meeting) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Champions Oncology Inc (NASDAQ: CSBR ) CureVac BV (NASDAQ: CVAC )(announced a vaccine supply deal with the European Commission) Eidos Therapeutics Inc (NASDAQ: EIDX ) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Infinity Pharmaceuticals Inc. (NASDAQ: INFI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kazia Therapeutics Ltd (NASDAQ: KZIA ) Keros Therapeutics Inc (NASDAQ: KROS ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim efficacy data for the Phase 3 study of its coronavirus vaccine candidate) Myokardia Inc (NASDAQ: MYOK ) Neuronetics Inc (NASDAQ: STIM ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacira Biosciences Inc (NASDAQ: PCRX ) Shockwave Medical Inc (NASDAQ: SWAV ) Spruce Biosciences Inc (NASDAQ: SPRB ) Summit Therapeutics Inc (NASDAQ: SMMT ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Tcr2 Therapeutics Inc (NASDAQ: TCRR ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) (announced regulatory filing for envafolimab in the indication of MSI-H/dMMR cancer, in China) Trinity Biotech plc (NASDAQ: TRIB ) United Therapeutics Corporation (NASDAQ: UTHR ) Veracyte Inc (NASDAQ: VCYT ) Vericel Corp (NASDAQ: VCEL ) Zai Lab Ltd – ADR (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov.
   Ocular Therapeutix™ To Report Third Quarter 2020 Financial Results  2020/10/23 11:00:00 Business Wire
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter financial results on Thursday, November 5, 2020. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern
   Traders Purchase Large Volume of Ocular Therapeutix Put Options (NASDAQ:OCUL)  2020/10/23 01:06:49 Stock Observer
Ocular Therapeutix, Inc. (NASDAQ:OCUL) saw unusually large options trading on Wednesday. Investors bought 2,424 put options on the company. This represents an increase of approximately 1,065% compared to the average daily volume of 208 put options. A number of analysts have commented on the company. BidaskClub downgraded Ocular Therapeutix from a “hold” rating to a […]
   Ocular Therapeutix Sees Unusually High Options Volume (NASDAQ:OCUL)  2020/10/22 02:04:42 US Banking News
Ocular Therapeutix, Inc. (NASDAQ:OCUL) saw some unusual options trading activity on Wednesday. Traders bought 2,424 put options on the company. This is an increase of approximately 1,065% compared to the typical volume of 208 put options. Shares of NASDAQ:OCUL opened at $10.53 on Thursday. The company has a debt-to-equity ratio of 8.86, a quick ratio […]
   The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout  2020/10/15 12:03:43 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14) 10X Genomics Inc (NASDAQ: TXG ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Denali Therapeutics Inc (NASDAQ: DNLI ) Immunomedics, Inc (NASDAQ: IMMU ) - The Hart-Scott-Rodino waiting period for its impending acquisition by Gilead Sciences, Inc. (NASDAQ: GILD ) expired, meeting one of the conditions necessary for the consummation of the transaction Insulet Corporation (NASDAQ: PODD ) Kronos Bio Inc (NASDAQ: KRON ) (went public Friday) Kura Oncology Inc (NASDAQ: KURA ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mirati Therapeutics Inc (NASDAQ: MRTX ) NeoGenomics, Inc (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Oncorus Inc (NASDAQ: ONCR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PRA Health Sciences Inc (NASDAQ: PRAH ) Replimune Group Inc (NASDAQ: REPL ) (abstract comprising data for its lead candidate RP1 in advanced solid tumors to be presented at the November Society for Immunotherapy of Cancer annual meeting made available online) Seres Therapeutics Inc (NASDAQ: MCRB ) SpringWorks Therapeutics Inc (NASDAQ: Full story available on Benzinga.
   Ocular Therapeutix under pressure on pricing ~$70M equity offering (NASDAQ:OCUL)  2020/10/14 10:35:18 Seeking Alpha
Ocular Therapeutix (NASDAQ:OCUL) has priced public offering of 7.18M common stock at $9.75/share, for gross proceeds of ~$70M. Underwriters' over-allotment

calendar